CVRx (NASDAQ:CVRX) Announces Earnings Results

CVRx (NASDAQ:CVRX) issued its earnings results on Monday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.01, Zacks reports. CVRx had a negative net margin of 94.10% and a negative return on equity of 99.32%.

Here are the key takeaways from CVRx’s conference call:

• CVRx reported a strong Q1, with total revenue of $14.8 million (+20%), U.S. revenue of $13.7 million (+22%), an improved gross margin of 87%, and a slightly smaller net loss, signaling that prior investments are beginning to drive commercial results.
• The transition to Category I CPT codes is a major reimbursement win, but new Medicare Advantage rules and payer automation produced a March dip in 30‑day prior‑authorization approvals (Q1 rate 46%), creating a near‑term administrative headwind that may add variability to access and timing of revenue.
• The BENEFIT‑HF randomized trial is underway (first site activated, first patient enrolled) and, if successful, could expand the addressable market from ~339,000 to >980,000 patients (~$30 billion TAM), although regulatory and enrollment timelines extend over several years.
• Commercial execution is improving — U.S. territories increased to 56 and active implanting centers to 257, and management reports higher utilization at targeted centers driven by a program‑focused sales approach, supporting sustained U.S. growth.
• Management reaffirmed 2026 guidance (revenue $63–67M, gross margin 85–87%, operating expenses $103–107M) despite the Q1 beat, reflecting a cautious posture early in the year while monitoring reimbursement and trial rollout trends.

CVRx Price Performance

Shares of CVRx stock traded up $0.09 during trading on Monday, hitting $6.92. The stock had a trading volume of 361,360 shares, compared to its average volume of 327,421. The firm has a market cap of $182.90 million, a price-to-earnings ratio of -3.38 and a beta of 0.90. CVRx has a 12 month low of $4.30 and a 12 month high of $11.30. The business’s 50-day moving average is $8.05 and its 200 day moving average is $8.05. The company has a current ratio of 7.63, a quick ratio of 6.72 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling at CVRx

In other news, Director Mudit K. Jain purchased 46,800 shares of the firm’s stock in a transaction dated Friday, February 20th. The shares were purchased at an average price of $6.36 per share, with a total value of $297,648.00. Following the completion of the acquisition, the director owned 980,183 shares in the company, valued at $6,233,963.88. This trade represents a 5.01% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CVRX. Virtu Financial LLC bought a new position in shares of CVRx in the fourth quarter worth $79,000. Corient Private Wealth LLC bought a new position in shares of CVRx in the fourth quarter worth $81,000. XTX Topco Ltd bought a new position in shares of CVRx in the fourth quarter worth $90,000. Alliancebernstein L.P. increased its stake in CVRx by 10.7% in the third quarter. Alliancebernstein L.P. now owns 17,560 shares of the company’s stock valued at $142,000 after acquiring an additional 1,700 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in CVRx by 61.3% in the fourth quarter. Wells Fargo & Company MN now owns 20,266 shares of the company’s stock valued at $144,000 after acquiring an additional 7,705 shares during the last quarter. Institutional investors own 75.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. Cantor Fitzgerald raised shares of CVRx to a “strong-buy” rating in a report on Tuesday, February 17th. Canaccord Genuity Group reissued a “buy” rating and set a $10.00 target price on shares of CVRx in a report on Tuesday, April 14th. Finally, Weiss Ratings cut shares of CVRx from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, CVRx has an average rating of “Buy” and an average target price of $11.50.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.